August 24, 2016 7:14am

… Speculation fuels the health and breath of “our” universe

With no solid fundamentals to depend on, investors should watch the depth and patterns of the oversolds as a means of obtaining an upside

… While these metrics leaves little to be desired, it reflects the state of the sector

 

Companies in my headlights: AGTC, CLLS, KOOL, OPXA and RGNX

Futures and indexes are MIXED

 

I answer one question; in which company should investors put, keep and commit their money!

 

Where is today’s market going? 

Subscribe and find out! 

 


 

Where do investors turn for insight and perspective - I say what others won't, so you can do what others can't!

 

 

Indexes and ETFs: The IBB (+0.11%), IWM (+0.06) are UP while the XLV is NOT indicating and the XBI (-0.05) is DOWN

Dow futures are UP +0.03% and NASDAQ futures are UP +0.06%

 

U.S. stock index futures pointed to a flat open on Wednesday, as investors concentrate on fluctuating oil prices and key data releases ahead of a key speech by the Fed's Chair.

European stocks were mostly higher, as investors eyed the volatility in oil prices, ahead of a key speech by U.S. the Fed’s Yellen on Friday.

Asia markets finished mixed, as traders remained in a wait-and-see mode ahead of Fed’s Yellen's speech at Jackson Hole on Friday.

 

 

Data docket: a slew of data is expected to keep investors on their toes, with the FHFA home price data and Existing home sales, due out at 9.00 a.m. and 10.00 a.m. ET respectively. Mortgage applications are also expected at 7.00 a.m. ET. Markets will also be keeping an eye on oil's reaction, after the crude inventories data comes out at 10.30 a.m. ET.

 

 

The stem, cell, gene and regenerative therapy (SCG&RT) sector closed NEGATIVE on Tuesday, POSITIVE on Monday, NEGATIVE on Friday, POSITIVE on Thursday and NEGATIVE last Wednesday.

The SCG&RT sector’s record after the last 5 days (of 43 covered companies):

  • Tuesday closed NEGATIVE with 28 decliners, 14 advancers and 1 flat;
  • Monday closed POSITIVE with 14 decliners, 27 advancers and 2 flats;
  • Friday closed NEGATIVE with 29 decliners, 13 advancers and 1 flat;
  • Thursday closed POSITIVE with 14 decliners,  26 advancers and 3 flats;
  • Last Wednesday closed NEGATIVE with 33 decliners, 9 advancers and 1 flat;

 

 

Remembering Tuesday’s closing post, “pricing drifts as the sector feels August’s disinterest.  This can be attributed to the sector itself – skepticism and the lack of news. Risk and performance reflect nomadic volume and fluctuating indicators.”

  • The key discrepancy that separates these short-term decreases from those advances that proceeded is the action of sector speculation.

The issue is a risk-on mindset.

  • Of course, too much of a bad thing can be disastrous, as is seen lately in this market.

I’m still holding on to “some” equities, recommending selling others and sticking my head in the sand until after Labor Day!

 

 

You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades? 

Watch list:

  • The iShares Nasdaq Biotechnology (IBB) closed Tuesday up +0.06% and is UP +0.11% in Wednesday’s pre-market;
  • The SPDR S&P Biotech ETF (XBI) closed Tuesday up +0.44% and is DOWN -0.05% in Wednesday’s  pre-market;
  • The Health Care Select Sector SPDR ETF (XLV) closed up Tuesday +0.09% and is NOT indicating in Wednesday’s pre-market;
  • The iShares Russell 2000 (IWM) closed up +0.71% on Tuesday and is UP +0.06% in Wednesday’s pre-market.

 

 

Companies in my headlights:

Applied Genetic Technologies (AGTC) closed DOWN -$0.19 to $14.63. It’s been a merry-go-round five days of trading, Monday’s $14.82, Friday’s $14.56, Thursday’s $14.83, Wednesday’s $15.13 and last Tuesday’s $15.23. Oversold – BUY;

Cellectis SA (CLLS) closed UP +$0.43 to $27.08. The aftermarket indication is negative -$1.11 and the chart looks trepidatious – SELL;

Cesca Therapeutics (KOOL) closed DOWN -$0.45 to $4.25 following Monday’s $4.70 (+$0.54). Spikes and bounces are prevalent in this equity, as evident by last week’s pricing Friday’s $4.16, $3.88, Wednesday’s $3.89, $3.90 Monday’s $4.20 and the previous Friday’s $3.96. The aftermarket indication is negative -$0.03 – Maintaining SELL;

Opexa (OPXA) closed UP +$0.26 to $4.69. It’s been a good five days post Monday’s $4.43, Friday’s $4.20, Thursday’s $4.27, Wednesday’s $4.16 and last Tuesday’s $4.16 and the previous Monday’s $4.13. Overbought and the chart looks “ripe” for the taking – SELL;

Regenxbio (RGNX) closed DOWN -$0.34 to $13.23 following Monday’s $13.57 (+$0.89). The chart is peaking, after Friday’s $12.68, Thursday’s $12.10, Wednesday’s $12.11, $12.19, last Friday’s $12.30 and the previous Monday’s $11.50. The target has a bull eyes for upsides in these “shallow” summer weeks – Maintaining SELL

 

 

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.